Goethe University Frankfurt
Verified
Frankfurt, Germany
Rare diseases
Investigational molecules
Locations
A plain-language summary of the goals, design and what participants do
This clinical trial is focused on studying treatments for Chronic Hepatitis B Virus Infection, a long-term infection of the liver caused by the hepatitis B virus. The study will explore the safety, tolerability, and effectiveness of different treatment combinations. The treatments being tested include VIR-2218, VIR-3434, and PEG-IFNα. VIR-2218 and VIR-3434 are solutions for injection, with VIR-2218 containing the active substance elebsiran and VIR-3434 containing tobevibart, a type of protein known as a monoclonal antibody. PEG-IFNα, also known as Pegasys, contains the active substance peginterferon alfa-2a and is also administered as an injection.
The purpose of this study is to evaluate how well these treatments work and how safe they are for people with chronic hepatitis B. Participants in the study will receive one or more of these treatments, or a placebo, over a period of up to 48 weeks. The study will monitor participants for any side effects and measure the effectiveness of the treatments in reducing the presence of the virus in the body. The study aims to find out if these treatments can help achieve a functional cure, which means the virus is no longer detectable in the blood and the liver functions normally.
Throughout the study, participants will have regular check-ups to monitor their health and the effects of the treatment. The study will also look at how the treatments affect specific markers of the virus in the blood, such as the levels of hepatitis B surface antigen (HBsAg) and hepatitis B virus DNA. The ultimate goal is to find a treatment regimen that is both safe and effective in managing or potentially curing chronic hepatitis B infection.
The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.
13 criteria
571 criteria
Tell us about your condition – we search every trial in Europe and connect you with the right site.
We usually reply within a few days
All sites with verified contact details – recruitment status may not be available; ask directly
Frankfurt, Germany
Hanover, Germany
Heidelberg, Germany
Where you can join this trial
Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.
Not recruitingJoining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.
is an investigational medication being studied for its potential to treat chronic Hepatitis B virus infection. It is designed to help reduce the levels of the virus in the body, potentially leading to better management of the infection.
is another investigational medication included in the study. It is being evaluated for its ability to work alongside other treatments to help control the Hepatitis B virus, aiming to improve the overall effectiveness of the treatment regimen.
(Pegylated Interferon Alpha) is a medication used to treat chronic Hepatitis B. It works by boosting the immune system to fight the virus, helping to reduce the amount of virus in the body and improve liver function.
This medication is administered through injection and is currently being studied in clinical trials for its potential to treat chronic Hepatitis B virus infection. It is not yet widely used in medical practice, as it is still under investigation. VIR-2218 works by targeting and reducing the production of viral proteins, which helps to control the infection. It is classified as an antiviral agent.
Administered via injection, VIR-3434 is also in clinical trials for chronic Hepatitis B virus infection. It is not yet approved for general medical use. The medication functions by binding to the virus, preventing it from entering liver cells and reducing viral load. VIR-3434 is classified as an antiviral agent.
This medication is given by injection and is used in the treatment of chronic Hepatitis B virus infection. It is well-documented in medical literature and is currently used in clinical practice. PEG-IFNα works by enhancing the immune system's response to the virus, helping to control the infection. It is classified as an immunomodulator.
sourced from the EU Clinical Trials Register and site verification
Want to learn more about this trial or check if you can participate?
Tell us about your condition – we search every trial in Europe and connect you with the right site.